Tempest Therapeutics (TPST) grants 1,230 stock options to director

Rhea-AI Filing Summary

Tempest Therapeutics director Nichol Geoffrey received a grant of stock options on January 27, 2026. The award covers 1,230 options to buy Tempest common stock at an exercise price of $2.94 per share, all held directly.

These options will vest in full on the earlier of January 27, 2027, or the day of Tempest’s 2026 annual stockholder meeting, if Geoffrey continues to serve through that date. Following this grant, he beneficially owns 1,230 derivative securities linked to Tempest shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NICHOL GEOFFREY

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.94	01/27/2026		A		1,230		(1)	01/26/2036	Common Stock	1,230	$0	1,230	D

Explanation of Responses:

1. The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Nicholas Maestas, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tempest Therapeutics (TPST) report for Nichol Geoffrey?

Tempest Therapeutics reported that director Nichol Geoffrey received 1,230 stock options on January 27, 2026. These derivative securities give him the right to buy common shares at a preset price and represent his current beneficial holdings from this grant.

How many Tempest Therapeutics (TPST) options were granted to director Nichol Geoffrey?

Nichol Geoffrey was granted 1,230 stock options tied to Tempest Therapeutics common stock. This entire amount is shown as beneficially owned following the transaction, reflecting a new equity incentive award rather than a sale or exercise of existing options.

What is the exercise price of Nichol Geoffrey’s Tempest Therapeutics (TPST) stock options?

The exercise price of the stock options granted to Nichol Geoffrey is $2.94 per share. This price is the amount he must pay per share to convert the options into Tempest common stock if and when he exercises them in the future.

When do Nichol Geoffrey’s Tempest Therapeutics (TPST) options vest?

The options vest in full on the earlier of January 27, 2027, or Tempest’s 2026 annual stockholder meeting date. Vesting is conditioned on Geoffrey’s continuous service with the company through that vesting date, aligning the award with ongoing board service.

Is the Tempest Therapeutics (TPST) Form 4 transaction a purchase or a grant?

The Form 4 reports an award of derivative securities coded as “A,” indicating a grant of stock options, not an open‑market purchase or sale. The options were issued at no upfront cost, with value realized only if exercised above the $2.94 exercise price.

How many Tempest Therapeutics (TPST) derivative securities does Nichol Geoffrey own after this filing?

After this reported grant, Nichol Geoffrey beneficially owns 1,230 derivative securities in the form of stock options. All of these options are held directly and relate to Tempest Therapeutics common stock under the company’s equity compensation arrangements.